Lisa Ricciardi, Cognition’s president and CEO, added, “Zervimesine delivered positive clinical data during 2024 from two key Phase 2 studies: the SHIMMER study in DLB and the SHINE study in Alzheimer’s disease. These results show the value that zervimesine holds as we advance towards Phase 3 clinical trials. Looking ahead, we will meet with the FDA on plans to start Phase 3 studies in Alzheimer’s disease and DLB. In parallel, we are actively evaluating options to fund our clinical trials, including potential partnering opportunities with pharmaceutical companies.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Is CGTX a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Cognition Therapeutics publishes research on zervimesine in dry AMD
- Cognition Therapeutics passes pre-defined futility analysis of Phase 2 study
- Cognition VP co-hosting workshop at Neuroimmunology Drug Development Summit